Plain-English translation of NCT04847635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing subthreshold laser treatment—a gentle form of laser therapy that uses lower energy than traditional lasers—to see if it can help protect your vision in people with reticular pseudodrusen, a condition where abnormal deposits form under the retina as part of age-related macular degeneration. The treatment aims to prevent these deposits from worsening into more serious damage (called atrophy) that can lead to severe vision loss. About half of participants will receive the actual laser treatment, while the other half will receive a sham procedure (where the laser device is positioned but the laser beam is not activated) so researchers can fairly compare results.
Age-related macular degeneration is a leading cause of vision loss in older adults, and reticular pseudodrusen is a challenging form of this disease that currently has few proven treatment options. This trial exists to find out whether this gentle laser approach can slow or prevent the progression to advanced vision loss.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the subthreshold laser treatment or the sham procedure. Over 12 months, you'll visit the clinic at baseline, then return for treatment and follow-up visits at months 3, 6, and 9. At your final visit at month 12, you'll have a comprehensive eye exam including vision testing, advanced imaging (OCT scans and eye blood vessel imaging), and special sensitivity testing to measure how well your retina is functioning. The researchers will compare how well your vision and retinal health are preserved in the laser treatment group versus the sham group.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy